Journal
ULTRASONICS SONOCHEMISTRY
Volume 84, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.ultsonch.2022.105972
Keywords
Sonodynamic therapy; Metal organic frameworks (MOFs); Infection diseases; Nanomedicine; Hemoglobin; Multidrug-resistant (MDR) bacteria
Categories
Funding
- University of Macau [MYRG 2020-00067-FHS, MYRG2019-00082-FHS, MYRG2018-00081-FHS]
- Macao Science and Technology Development Fund [FDCT 0011/2018/A1, FDCT 0020/2019/AMJ]
- Guangdong Natural Science Foundation [EF017/FHS-YZ/2021/GDSTCRSKTO]
- Shenzhen Basic Research Project [JCYJ20180305125425815]
- Guangdong-Hong Kong-Macao Greater Bay Area Center for Brain Sci-ence and Brain-Inspired Intelligence Fund [2019011]
- [0020/2019/AMJ]
Ask authors/readers for more resources
This study successfully developed a new nanosonosensitizer for sonodynamic therapy, which can effectively kill multidrug-resistant bacteria and treat infection diseases. The nanosonosensitizer exhibits enhanced water-solubility, good biocompatibility, and improved disease-targeting capability. Moreover, it can augment the efficacy of sonodynamic therapy by improving ROS generating efficiency against deep tissue multidrug-resistant bacterial infection.
Among various novel antimicrobial therapies, sonodynamic therapy (SDT) exhibits its advantages for the treatment of bacterial infections due to its high penetration depth and low side effects. In this study, a new nanosonosensitizer (HFH@ZIF-8) that loads sonosensitizer hematoporphyrin monomethyl ether (HMME) into zeolitic imidazolate framework-8 (ZIF-8), was constructed for killing multidrug-resistant (MDR) bacteria and treatment of in vivo infection diseases by SDT. In particular, the developed HFH@ZIF-8 exhibited enhanced water-solubility, good biocompatibility, and improved disease-targeting capability for delivering and releasing HMME and ablating the infected lesion. More importantly, the presence of oxygen-carrying hemoglobin for HFH@ZIF-8 can offer sufficient oxygen consumption by SDT, augmenting the efficacy of SDT by improving ROS generating efficiency against deep tissue multidrug-resistant bacterial infection. Therefore, this study paves a new avenue for treating infection disease, particularly for antibiotic resistant bacterial infection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available